Filgotinib

Filgotinib

Filgotinib is a Janus kinase inhibitor developed by Gilead Sciences and Galapagos NV for the treatment of rheumatoid arthritis, ulcerative colitis, and Crohn's disease. It is a selective JAK1 inhibitor with IC50 of 10 nM, approximately 28-fold selective for JAK1 over JAK2.

History

Filgotinib was initially developed by the Belgian company Galapagos NV. In 2015, Gilead Sciences acquired the rights to the drug for $2 billion. The drug was submitted for approval in the European Union (EU) and Japan in 2019, and was approved in the EU in September 2020 under the brand name Jyseleca.

Mechanism of Action

Filgotinib is a Janus kinase inhibitor, which works by blocking the action of one or more of a specific family of enzymes, interfering with the pathway that leads to inflammation. It is a selective JAK1 inhibitor, which means it primarily blocks the Janus kinase 1 (JAK1) enzyme.

Clinical Trials

Several clinical trials have been conducted to evaluate the efficacy and safety of Filgotinib. These include Phase 2 and 3 trials for rheumatoid arthritis, ulcerative colitis, and Crohn's disease. The results have shown that Filgotinib is effective in reducing symptoms and improving quality of life in patients with these conditions.

Side Effects

Common side effects of Filgotinib include nausea, upper respiratory tract infection, and urinary tract infection. Serious side effects may include serious infections, cancers, and blood clots.

See Also

• Janus kinase inhibitor
• Rheumatoid arthritis
• Ulcerative colitis
• Crohn's disease

This article is a stub related to pharmacology. You can help WikiMD by expanding it!